Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...

New treatments can slow the disease’s progress, which is why the Alzheimer’s Association is leveraging its celebrity partners ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement ...

BioArctic AB's (publ) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as sales of Leqembi reached ?

Lecanemab (brand name LEQEMBI®) is a new medication used to treat the very early stages of Alzheimer's disease. Your patients may have questions about this treatment and be looking for more ...

Hilary Evans-Newton is the Chief Executive of Alzheimer’s Research UK. Hilary joined Alzheimer’s Research UK in 2013 and has overseen significant growth in income in recent years, which has ...

BioArctic signed the first deal for its “brain transporter” with Bristol Myers Squibb late last year. The deal is worth up to $1.4bn and allows the US drugmaker to start trials using the technology to ...

More than a decade after hosting clinical trials for two medications now commonly used to slow the progression of Alzheimer’s ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Here is a look at Alzheimer’s disease, a progressive brain disorder that leads to loss of memory and other intellectual abilities. Facts Alzheimer’s disease is the most common form of dementia, which ...

Woody Anderson has always been a storyteller. “I’ve written 6,700 stories,” said Anderson, who worked for the Hartford ...